Newsfeeds - Spark Newswire

1 minute read

Earnings

Recap: Onconova Therapeutics Q2 Earnings

Today, 5:37 PM

Shares of Onconova Therapeutics (NASDAQ:ONTX) moved higher by 2.1% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 575.00% over the past year to ($0.27), which beat the estimate of ($0.28).

ONTX

1 minute read

Onconova Therapeutics Q2 EPS $(0.27) Beats $(0.28) Estimate, Sales $57.00K Beat $20.00K Estimate

By Bill Haddad

Today, 5:37 PM

Onconova Therapeutics (NASDAQ:ONTX) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.28) by 3.57 percent. This is a 575 percent decrease over losses of $(0.04) per share

ONTX

5 minute read

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma

By Shanthi Rexaline

Today, 5:37 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)

ABCL

15 minute read

Earnings Scheduled For August 12, 2021

By Benzinga Insights

Today, 5:37 PM

Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.

AACG

7 minute read

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

By Shanthi Rexaline

Today, 5:37 PM

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.

ABCL

3 minute read

Onconova Therapeutics Provides Update Oh Phase 1/2 Trial Of Rigosertib-Nivolumab Combination; Says Expansion Of Trial Underway At Highest Dose

By Bill Haddad

Today, 5:37 PM

Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration Preliminary data support the preclinical observation of rigosertib augmenting the response to

ONTX

2 minute read

FDA
News

Onconova Therapeutics Announces Peer-Reviewed Publication Of Preclinical Data Demonstrating Synergistic Anti-Cancer Activity Of Rigosertib Combined With Immune Checkpoint Blockade

By Benzinga Newsdesk

Today, 5:37 PM

Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication

ONTX

2 minute read

22 Stocks Moving in Tuesday’s Pre-Market Session

By Lisa Levin

Today, 5:37 PM

Gainers Unique Fabricating, Inc. (NASDAQ: UFAB) rose 43.1% to $4.68 in pre-market trading after the company announced the extension of its Forbearance Agreement with its Lenders through February 28, 2022.

ATXI

4 minute read

Uncategorized

52 Biggest Movers From Yesterday

By Lisa Levin

Today, 5:37 PM

Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA, its distinctive immuno-oncology RNA therapy for the treatment of multiple cancers.

ALT

4 minute read

Uncategorized

48 Biggest Movers From Friday

By Lisa Levin

Today, 5:37 PM

Gainers

ADES